Clinical trials
Phase 2 Carotid Stenosis trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
23 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2012 | 2 |
| 2013 | 2 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 4 |
| 2018 | 2 |
| 2019 | 1 |
| 2021 | 1 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 7 |
| Terminated | 6 |
| Unknown status | 4 |
| Withdrawn | 2 |
| Recruiting | 2 |
| Suspended | 1 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Brigham and Women's Hospital | 2 |
| AdvanceCor GmbH | 1 |
| Advanced Accelerator Applications | 1 |
| Archemix Corp. | 1 |
| Capital Medical University | 1 |
| Emory University | 1 |
| Guangzhou University of Traditional Chinese Medicine | 1 |
| Hospices Civils de Lyon | 1 |
| Ji Xunming | 1 |
| Mayo Clinic | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carotid Stenosis | 23 |
| Cerebrovascular Disorders | 4 |
| Inflammation | 4 |
| Stroke | 4 |
| Atherosclerosis | 3 |
| Carotid Artery Diseases | 3 |
| Cardiovascular Diseases | 2 |
| Heart Diseases | 2 |
| Vascular Diseases | 2 |
| Amaurosis Fugax | 1 |
Trials
Showing 51 to 23 of 23. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.